# EDGAR Filing Document

**Accession Number:** 0001814423
**File Stem:** 0001104659-25-062804
**Filing Date:** 2025-6
**Character Count:** 23353
**Document Hash:** 05ac5a699b749786c0265a7d1439a1d7
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-062804.hdr.sgml**: 20250626

**ACCESSION NUMBER**: 0001104659-25-062804

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20250626

**FILED AS OF DATE**: 20250626

**DATE AS OF CHANGE**: 20250626

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** iHuman Inc.
- **CENTRAL INDEX KEY:** 0001814423
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-EDUCATIONAL SERVICES [8200]
- **ORGANIZATION NAME:** 07 Trade & Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39591
- **FILM NUMBER:** 251075085

**BUSINESS ADDRESS:**
- **STREET 1:** FLOOR 8, BUILDING 2,
- **STREET 2:** NO.1 WANGJING EAST RD, CHAOYANG DISTRICT
- **CITY:** BEIJING
- **STATE:** F4
- **ZIP:** 100102
- **BUSINESS PHONE:** 86-10-5780-6636

**MAIL ADDRESS:**
- **STREET 1:** FLOOR 8, BUILDING 2,
- **STREET 2:** NO.1 WANGJING EAST RD, CHAOYANG DISTRICT
- **CITY:** BEIJING
- **STATE:** F4
- **ZIP:** 100102

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16 UNDER**

**THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of June 2025**

**Commission File Number: 001-39591**

**iHuman Inc.**

(Registrant's Name)

**Building A,<br> No. 1 Wangjing East Road,<br> Chaoyang District, Beijing 100102**

**People's Republic of China**

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ⌧ Form 40-F ◻

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| [99.1](tm2519072d1_ex99-1.htm) | [Press Release](tm2519072d1_ex99-1.htm) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| **iHuman Inc.** | **iHuman Inc.** | **iHuman Inc.** |
| By | : | /s/ Vivien Weiwei Wang |
| Name | : | Vivien Weiwei Wang |
| Title | : | Director and Chief Financial Officer |

---

Date: June 26, 2025

## Exhibit 99.1

**Exhibit 99.1**

![](tm2519072d1_ex99-1img01.jpg)

**iHuman Inc. Announces First Quarter 2025 Unaudited Financial Results**

BEIJING, China, Jun. 26, 2025 -- iHuman Inc. (NYSE: IH) ("iHuman" or the "Company"), a leading provider of tech-powered, intellectual development products in China, today announced its unaudited financial results for the first quarter ended March 31, 2025.

**<u>First Quarter 2025 Highlights</u>**

· Revenues were RMB210.4 million
(US$29.0 million), compared with RMB235.0 million in the same period last year.

· Gross profit was RMB143.8 million
(US$19.8 million), compared with RMB168.1 million in the same period last year.

· Operating income was RMB21.6
million (US$3.0 million), compared with RMB17.5 million in the same period last year.

· Net income was RMB26.5 million
(US$3.7 million), compared with RMB22.3 million in the same period last year.

· Average total MAUs<sup>1</sup>
for the first quarter were 26.51 million, compared with 26.38 million in the same period last year.

Dr. Peng Dai, Director and Chief Executive Officer of iHuman, commented, "This quarter, we continued to drive innovation across our product portfolio while further strengthening our international industry partnerships.

Our flagship offerings maintain strong user engagement and a prominent market presence as they continue to deliver value to our users. During the quarter, *iHuman Chinese* expanded its content library with a broader set of Chinese characters, growing from 1,300 to 1,800 in total, offering children a more comprehensive and engaging experience. In *iHuman Magic Thinking*, we introduced a new module focused on applied problem-solving, using short, animated sessions to help children apply math concepts to real-life scenarios in a clear and accessible way.

In a continued effort to innovate, we also expanded our smart device portfolio with the launch of *iHuman All-Subject Master*, a budget-friendly device designed to help young children build foundational skills with minimal setup and guidance. With a built-in screen, tactile input, and voice interaction, the device delivers a multi-sensory experience that encourages independent engagement. Through thoughtfully designed content blending visual cues, spoken prompts, and interactive challenges, it supports the development of core language, numeracy, and critical thinking skills in a natural and enjoyable way.

As part of our industry collaboration efforts, we held in-depth discussions with Oxford University Press (OUP) at its UK headquarters in May. Together, we explored cooperation opportunities around OUP's trusted content resources, children's literature, and English proficiency assessments for young learners with a shared goal of accelerating the upgrade of our English offerings. To date, our English product line has already incorporated 25 original OUP reading series from around the globe, covering over 1,000 titles for children aged 3 to 12, and Oxford Primary English Reading Assessments for young learners. These resources are now fully integrated into our platform, enabling intelligent, age- and level-based recommendations. We also jointly developed the *Fantastic Friends* IP and a comprehensive English learning solution tailored for elementary school students. By combining world-class English learning resources with our cutting-edge interactive content and smart learning engines, we are committed to helping children build confidence and strength in English.

<sup>1</sup> "Average total MAUs" refers to the monthly average of the sum of the MAUs of each of the Company's apps during a specific period, which is counted based on the number of unique mobile devices through which such app is accessed at least once in a given month, and duplicate access to different apps is not eliminated from the total MAUs calculation.

Looking ahead, we remain focused on developing high-quality, impactful products that empower children's holistic growth, while steadily expanding our global footprint to reach more families around the world."

This effort also reflects our ongoing commitment to delivering innovative, future-ready solutions that meet the evolving needs of young learners while laying a solid foundation for our long-term growth."

**<u>First Quarter 2025 Unaudited Financial Results</u>**

***Revenues***

Revenues were RMB210.4 million (US$29.0 million), compared with RMB235.0 million in the same period last year. The decrease in revenues was primarily due to the decline in China's newborn population and more conservative consumer spending.

Average total MAUs for the quarter were 26.51 million, compared with 26.38 million in the same period last year.

***Cost of Revenues***

Cost of revenues was RMB66.7 million (US$9.2 million), compared with RMB66.9 million in the same period last year.

***Gross Profit and Gross Margin***

Gross profit was RMB143.8 million (US$19.8 million), compared with RMB168.1 million in the same period last year. Gross margin was 68.3%, compared with 71.5% in the same period last year. The decrease in gross margin was mainly due to the diversification and structural upgrades of the Company's product portfolio, especially with an increased focus on the offline component of its integrated online-offline strategy to boost the overall appeal of its offerings.

***Operating Expenses***

Total operating expenses were RMB122.2 million (US$16.8 million), a decrease of 18.9% from RMB150.6 million in the same period last year.

Research and development expenses were RMB55.4 million (US$7.6 million), a decrease of 18.5% from RMB67.9 million in the same period last year, primarily due to savings in payroll-related costs.

Sales and marketing expenses were RMB41.3 million (US$5.7 million), a decrease of 25.0% from RMB55.0 million in the same period last year, primarily due to cost savings in marketing activities.

General and administrative expenses were RMB25.5 million (US$3.5 million), a decrease of 7.9% from RMB27.7 million in the same period last year, primarily due to savings in professional fees.

***Operating Income***

Operating income was RMB21.6 million (US$3.0 million), compared with RMB17.5 million in the same period last year.

***Net Income***

Net income was RMB26.5 million (US$3.7 million), compared with RMB22.3 million in the same period last year.

Basic and diluted net income per ADS were RMB0.51 (US$0.07) and RMB0.49 (US$0.07), respectively, compared with RMB0.42 and RMB0.41 in the same period last year. Each ADS represents five Class A ordinary shares of the Company.

***Deferred Revenue and Customer Advances***

Deferred revenue and customer advances were RMB267.9 million (US$36.9 million) as of March 31, 2025, compared with RMB283.3 million as of December 31, 2024.

***Cash, Cash Equivalents and Short-term Investments***

Cash, cash equivalents and short-term investments were RMB1,119.1 million (US$154.2 million) as of March 31, 2025, compared with RMB1,168.7 million as of December 31, 2024. The decrease was primarily due to the payment of annual bonuses to employees in the first quarter.

**<u>Exchange Rate Information</u>**

The U.S. dollar (US$) amounts disclosed in this press release, except for those transaction amounts that were actually settled in U.S. dollars, are presented solely for the convenience of the reader. The conversion of Renminbi (RMB) into US$ in this press release is based on the exchange rate set forth in the H.10 statistical release of the Board of Governors of the Federal Reserve System as of March 31, 2025, which was RMB7.2567 to US$1.00. The percentages stated in this press release are calculated based on the RMB amounts.

**<u>Non-GAAP Financial Measures</u>**

iHuman considers and uses non-GAAP financial measures, such as adjusted operating income, adjusted net income and adjusted diluted net income per ADS, as supplemental metrics in reviewing and assessing its operating performance and formulating its business plan. The presentation of non-GAAP financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"). iHuman defines adjusted operating income, adjusted net income and adjusted diluted net income per ADS as operating income, net income and diluted net income per ADS excluding share-based compensation expenses, respectively. Adjusted operating income, adjusted net income and adjusted diluted net income per ADS enable iHuman's management to assess its operating results without considering the impact of share-based compensation expenses, which are non-cash charges. iHuman believes that these non-GAAP financial measures provide useful information to investors in understanding and evaluating the Company's current operating performance and prospects in the same manner as management does, if they so choose.

Non-GAAP financial measures are not defined under U.S. GAAP and are not presented in accordance with U.S. GAAP. Non-GAAP financial measures have limitations as analytical tools, which possibly do not reflect all items of expense that affect our operations. Share-based compensation expenses have been and may continue to be incurred in our business and are not reflected in the presentation of the non-GAAP financial measures. In addition, the non-GAAP financial measures iHuman uses may differ from the non-GAAP measures used by other companies, including peer companies, and therefore their comparability may be limited. The presentation of these non-GAAP financial measures is not intended to be considered in isolation from or as a substitute for the financial information prepared and presented in accordance with GAAP.

**<u>Safe Harbor Statement</u>**

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Statements that are not historical facts, including statements about iHuman's beliefs and expectations, are forward-looking statements. Among other things, the description of the management's quotations in this announcement contains forward-looking statements. iHuman may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the "SEC"), in its annual report to shareholders, in press releases and other written materials, and in oral statements made by its officers, directors or employees to third parties. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: iHuman's growth strategies; its future business development, financial condition and results of operations; its ability to continue to attract and retain users, convert non-paying users into paying users and increase the spending of paying users, the trends in, and size of, the market in which iHuman operates; its expectations regarding demand for, and market acceptance of, its products and services; its expectations regarding its relationships with business partners; general economic and business conditions; regulatory environment; and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in iHuman's filings with the SEC. All information provided in this press release is as of the date of this press release, and iHuman does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

**<u>About iHuman Inc.</u>**

iHuman Inc. is a leading provider of tech-powered, intellectual development products in China that is committed to making the child-upbringing experience easier for parents and transforming intellectual development into a fun journey for children. Benefiting from a deep legacy that combines over two decades of experience in the parenthood industry, superior original content, advanced high-tech innovation DNA and research & development capabilities with cutting-edge technologies, iHuman empowers parents with tools to make the child-upbringing experience more efficient. iHuman's unique, fun and interactive product offerings stimulate children's natural curiosity and exploration. The Company's comprehensive suite of innovative and high-quality products include self-directed apps, interactive content and smart devices that cover a broad variety of areas to develop children's abilities in speaking, critical thinking, independent reading and creativity. Leveraging advanced technological capabilities, including 3D engines, AI/AR functionality, and big data analysis on children's behavior & psychology, iHuman believes it will continue to provide superior experience that is efficient and relieving for parents, and effective and fun for children, in China and all over the world, through its integrated suite of tech-powered, intellectual development products.

For more information about iHuman, please visit https://ir.ihuman.com/.

**For investor and media enquiries, please contact:**

**iHuman Inc.**

Mr. Justin Zhang

Investor Relations Director

Phone: +86-10-5780-6606

E-mail: <u>ir@ihuman.com</u>

**Christensen**

In China

Ms. Alice Li

Phone: +86-10-5900-1548

E-mail: <u>alice.li@christensencomms.com</u>

In the US

Ms. Linda Bergkamp

Phone: +1-480-614-3004

E-mail: <u>linda.bergkamp@christensencomms.com</u>

**iHuman Inc.**

**UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS**

**(Amounts in thousands of Renminbi ("RMB") and U.S. dollars ("US$")**

**except for number of shares, ADSs, per share and per ADS data)**

---

| | | | |
|:---|:---|:---|:---|
|  | **December 31,**<br>**2024** | **March 31,**<br>**2025** | **March 31,**<br>**2025** |
|  | **RMB** | **RMB** | **US$** |
| **ASSETS** |  |  |  |
| &nbsp;&nbsp;&nbsp;**Current assets** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | 1123292 | 1119064 | 154211 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Short-term investments | 45457 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net | 52030 | 59578 | 8210 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories, net | 23475 | 18935 | 2609 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amounts due from related parties | 2051 | 1449 | 200 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepayments and other current assets | 89512 | 90290 | 12442 |
| &nbsp;&nbsp;&nbsp;**Total current assets** | **1335817** | **1289316** | **177672** |
| &nbsp;&nbsp;&nbsp;**Non-current assets** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Property and equipment, net | 3476 | 3026 | 417 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Intangible assets, net | 16429 | 16075 | 2215 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating lease right-of-use assets | 14885 | 14064 | 1938 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Long-term investment | 26333 | 26333 | 3629 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other non-current assets | 22701 | 23377 | 3221 |
| &nbsp;&nbsp;&nbsp;**Total non-current assets** | **83824** | **82875** | **11420** |
| **Total assets** | **1419641** | **1372191** | **189092** |
| **LIABILITIES** |  |  |  |
| &nbsp;&nbsp;&nbsp;**Current liabilities** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | 30233 | 24363 | 3357 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred revenue and customer advances | 283251 | 267916 | 36920 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amounts due to related parties | 1734 | 7427 | 1023 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses and other current liabilities | 126501 | 80216 | 11054 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dividend payable | 2164 | 37062 | 5107 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Current operating lease liabilities | 3661 | 3576 | 493 |
| &nbsp;&nbsp;&nbsp;**Total current liabilities** | **447544** | **420560** | **57954** |
| &nbsp;&nbsp;&nbsp;**Non-current liabilities** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-current operating lease liabilities | 11252 | 10586 | 1459 |
| &nbsp;&nbsp;&nbsp;**Total non-current liabilities** | **11252** | **10586** | **1459** |
| **Total liabilities** | **458796** | **431146** | **59413** |
| **SHAREHOLDERS' EQUITY** |  |  |  |
| &nbsp;&nbsp;&nbsp;Ordinary shares (par value of US$0.0001 per share, 700,000,000 Class A shares authorized as of December 31, 2024 and March 31, 2025; 125,122,382 Class A shares issued and 116,084,207 outstanding as of December 31, 2024; 125,122,382 Class A shares issued and 113,607,892 outstanding as of March 31, 2025; 200,000,000 Class B shares authorized, 144,000,000 Class B ordinary shares issued and outstanding as of December 31, 2024 and March 31, 2025; 100,000,000 shares (undesignated) authorized, nil shares (undesignated) issued and outstanding as of December 31, 2024 and March 31, 2025) | 185 | 185 | 25 |
| &nbsp;&nbsp;&nbsp;Additional paid-in capital | 996657 | 959954 | 132285 |
| &nbsp;&nbsp;&nbsp;Treasury stock | (26296) | (35319) | (4867) |
| &nbsp;&nbsp;&nbsp;Statutory reserves | 8395 | 8395 | 1157 |
| &nbsp;&nbsp;&nbsp;Accumulated other comprehensive income | 24009 | 23417 | 3227 |
| &nbsp;&nbsp;&nbsp;Accumulated deficit | (42105) | (15587) | (2148) |
| **Total shareholders' equity** | **960845** | **941045** | **129679** |
| **Total liabilities and shareholders' equity** | **1419641** | **1372191** | **189092** |

---

**iHuman Inc.**

**UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**

**(Amounts in thousands of Renminbi ("RMB") and U.S. dollars ("US$")**

**except for number of shares, ADSs, per share and per ADS data)**

---

| | | | |
|:---|:---|:---|:---|
|  | **For the three months ended** | **For the three months ended** | **For the three months ended** |
|  | **March 31,**<br>**2024** | **March 31,**<br>**2025** | **March 31,**<br>**2025** |
|  | **RMB** | **RMB** | **US$** |
| **Revenues** | **235003** | **210439** | **28999** |
| **Cost of revenues** | **(66892)** | **(66663)** | **(9186)** |
| **Gross profit** | **168111** | **143776** | **19813** |
| **Operating expenses** |  |  |  |
| &nbsp;&nbsp;&nbsp;Research and development expenses | (67923) | (55385) | (7632) |
| &nbsp;&nbsp;&nbsp;Sales and marketing expenses | (54995) | (41255) | (5685) |
| &nbsp;&nbsp;&nbsp;General and administrative expenses | (27724) | (25539) | (3519) |
| **Total operating expenses** | **(150642)** | **(122179)** | **(16836)** |
| **Operating income** | **17469** | **21597** | **2977** |
| &nbsp;&nbsp;&nbsp;Other income, net | 9010 | 8000 | 1102 |
| **Income before income taxes** | **26479** | **29597** | **4079** |
| &nbsp;&nbsp;&nbsp;Income tax expenses | (4177) | (3079) | (424) |
| **Net income** | **22302** | **26518** | **3655** |
| **Net income per ADS:** |  |  |  |
| &nbsp;&nbsp;&nbsp;- Basic | 0.42 | 0.51 | 0.07 |
| &nbsp;&nbsp;&nbsp;- Diluted | 0.41 | 0.49 | 0.07 |
| **Weighted average number of ADSs:** |  |  |  |
| &nbsp;&nbsp;&nbsp;- Basic | 52729148 | 51888345 | 51888345 |
| &nbsp;&nbsp;&nbsp;- Diluted | 54691599 | 53884134 | 53884134 |
| **Total share-based compensation expenses included in:** |  |  |  |
| &nbsp;&nbsp;&nbsp;Cost of revenues | 40 | 8 | 1 |
| &nbsp;&nbsp;&nbsp;Research and development expenses | 457 | 110 | 15 |
| &nbsp;&nbsp;&nbsp;Sales and marketing expenses | 46 | 16 | 2 |
| &nbsp;&nbsp;&nbsp;General and administrative expenses | 301 | 104 | 14 |

---

**iHuman Inc.**

**UNAUDITED RECONCILIATION OF GAAP AND NON-GAAP RESULTS**

**(Amounts in thousands of Renminbi ("RMB") and U.S. dollars ("US$")**

**except for number of shares, ADSs, per share and per ADS data)**

---

| | | | |
|:---|:---|:---|:---|
|  | **For the three months ended** | **For the three months ended** | **For the three months ended** |
|  | **March 31,**<br>**2024** | **March 31,**<br>**2025** | **March 31,**<br>**2025** |
|  | **RMB** | **RMB** | **US$** |
| **Operating income** | **17469** | **21597** | **2977** |
| Share-based compensation expenses | 844 | 238 | 32 |
| **Adjusted operating income** | **18313** | **21835** | **3009** |
| **Net income** | **22302** | **26518** | **3655** |
| Share-based compensation expenses | 844 | 238 | 32 |
| **Adjusted net income** | **23146** | **26756** | **3687** |
| Diluted net income per ADS | 0.41 | 0.49 | 0.07 |
| Impact of non-GAAP adjustments | 0.01 | 0.01 | 0.00 |
| **Adjusted diluted net income per ADS** | **0.42** | **0.50** | **0.07** |
| Weighted average number of ADSs – diluted | 54691599 | 53884134 | 53884134 |
| **Weighted average number of ADSs – adjusted** | **54691599** | **53884134** | **53884134** |

---